Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederglobenewswire.com
GlobeNewswire - News about Public Companies
Get the latest updates from GlobeNewswire - News about Public Companies directly as they happen.
Follow now 120 followers
Latest posts
Last updated about 4 hours ago
Perseus Mining Increases Share Buy-Back from AUD100M to AUD 150M
about 4 hours ago
Perth, June 15, 2026 (GLOBE NEWSWIRE) -- PERSEUS INCREASES ON-MARKET SHARE BUY-BACK...
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
about 4 hours ago
ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage...
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
about 5 hours ago
VANCOUVER, British Columbia, June 14, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq...
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
about 7 hours ago
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of...
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
about 9 hours ago
Data from up to two years of treatment in PATHFNDR-1 and PATHFNDR-2...
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
about 13 hours ago
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today...
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
about 13 hours ago
– Verekitug, administered once every three months, led to clinically meaningful improvements...
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
about 13 hours ago
– Lorundrostat was associated with significant reductions in heart failure risk biomarkers...
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
about 18 hours ago
HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented...
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
about 20 hours ago
BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ...
Air Canada and the IAMAW Reach Tentative Agreement on New Contract
1 day ago
MONTRÉAL, June 13, 2026 (GLOBE NEWSWIRE) -- Air Canada today said it...
Air Canada et l’AIMTA concluent une entente de principe sur une nouvelle convention collective
1 day ago
MONTRÉAL, 13 juin 2026 (GLOBE NEWSWIRE) -- Air Canada a annoncé aujourd’hui...